Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study

Sorafenib, an oral multikinase inhibitor, is approved for advanced hepatocellular carcinoma (HCC) treatment. However, its therapeutic effect in advanced HCC patients with extrahepatic metastasis remains uncertain. This study aimed to prospectively assess the efficacy, safety, and survival risk facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Masahito, Tanaka, Masatoshi, Kuromatsu, Ryoko, Nagamatsu, Hiroaki, Tajiri, Nobuyoshi, Satani, Manabu, Niizeki, Takashi, Aino, Hajime, Okamura, Shusuke, Iwamoto, Hideki, Shimose, Shigeo, Shirono, Tomotake, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123720/
https://www.ncbi.nlm.nih.gov/pubmed/26471348
http://dx.doi.org/10.1002/cam4.548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123720/
https://www.ncbi.nlm.nih.gov/pubmed/26471348
http://dx.doi.org/10.1002/cam4.548

Ejemplares similares